PERSPECTIVE THERAPEUTICS, INC. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
PERSPECTIVE THERAPEUTICS, INC. (CATX) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $2.08 million as of 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-03-16
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $2.08M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $1.44M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $2.55M; Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost as first filed $3.21M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $722.00K.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost as first filed |
|---|---|---|
| 2025-12-31 | $2.08M 10-K · filed 2026-03-16 | |
| 2024-12-31 | $1.44M 10-K · filed 2026-03-16 | |
| 2023-12-31 | $2.55M 10-K/A · filed 2025-03-28 | $3.21M 10-K · filed 2024-03-28 |
| 2022-12-31 | $722.00K 10-K · filed 2024-03-28 | |
| 2022-06-30 | $525.00K 10-KT · filed 2023-05-01 | |
| 2021-06-30 | $563.00K 10-KT · filed 2023-05-01 | |
| 2020-06-30 | $682.00K 10-K · filed 2021-09-27 | |
| 2019-06-30 | $578.00K 10-K · filed 2020-09-25 | |
| 2018-06-30 | $480.00K 10-K · filed 2019-09-27 | |
| 2017-06-30 | $664.00K 10-K · filed 2018-09-26 | |
| 2016-06-30 | $545.00K 10-K · filed 2017-09-28 | |
| 2015-06-30 | $443.00K 10-K · filed 2016-09-09 | $443.20K 10-K · filed 2015-09-14 |
| 2014-06-30 | $371.36K 10-K · filed 2015-09-14 | |
| 2013-06-30 | $279.09K 10-K · filed 2014-09-29 | |
| 2012-06-30 | $241.17K 10-K · filed 2013-09-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |